EVENTS | VIEW CALENDAR
SV Bio, Mayo Clinic join forces
ROCHESTER, Minn.—Mayo Clinic and Silicon Valley Biosystems (SV Bio) have announced the establishment of a strategic collaboration for whole genome diagnostics and interpretation at two sites: the Mayo Clinic Center for Individualized Medicine and Mayo Medical Laboratories.
"At Mayo Clinic, we are committed to integrating genomic medicine into the continuum of care for all of our patients," Gianrico Farrugia, M.D., director of the Mayo Clinic Center for Individualized Medicine, said in a press release. "The Individualized Medicine Clinic represents one of Mayo's bold steps toward realizing the promise of these game-changing technologies and toward offering new hope to patients, including those with cancer and diagnostic dilemmas."
Per the agreement, SV Bio's proprietary genome interpretation solution and Mayo Clinic's genome reference library will be brought together in hopes of increasing accessibility to and clinical use of next-generation sequencing for patients. SV Bio will make available its clinical genome interpretation services and clinical decision support interfaces to Mayo Clinic, and the Center for Individualized Medicine will provide clinical and laboratory support and expertise. No financial details were disclosed.
"Every human disease has a genetic component but, to date, medical providers have not been able to fully utilize this information to improve clinical outcomes. With the SV Bio platform, we've made the translation to a single assay — a full human genome — with the diagnostics rapidly and precisely happening in silico," Dietrich Stephan, Ph.D., founder, president and CEO of SV Bio, said in a statement.
SV Bio's process is fully computerized and automated, allowing for clinically actionable genome interpretation in a matter of minutes rather than weeks. While genome sequencing is gaining popularity as the cost continues to drop, the volume of data that results remains an issue in terms of managing, interpreting and making use of it across the board. SV Bio's technology evaluates a patient's genome at the point of care and distills it, providing physicians with concise, actionable reports that allow for more informed decisions, and the partners will seek to unlock the potential of next-generation sequencing and make these technologies available for all patients.
"In our laboratories, we are rapidly adopting and implementing next-generation sequencing as a platform upon which we will be providing cutting-edge genome-based testing," Franklin Cockerill, M.D., president of Mayo Medical Laboratories, noted in a press release. "This collaboration with SV Bio furthers our mission of bringing the latest diagnostic technologies to health care providers around the world."
"We are now able to take data from any next-generation sequencer and determine with clinical-grade sensitivity and specificity which variants within a patient's DNA sequence are influencing a disease or condition, and rapidly provide a report for the clinician that is clear and actionable," said Stephan. "This level of speed, accuracy and integration into the clinical work flow is not only a first for molecular testing, but also a sea change in the application of next-generation sequencing with no compromise of quality in clinical diagnostics."
SOURCE: SV Bio press release